S Rivers
Overview
Explore the profile of S Rivers including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
68
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Allan K, Masters N, Rivers S, Berry K, Routh A, Lamm C
J Comp Pathol
. 2014 Jan;
150(2-3):345-9.
PMID: 24444818
A 10-year-old captive male Siberian tiger (Panthera tigris altaica) presented with acute onset collapse, vomiting and dyspnoea, preceded by a 6-month period of progressive muscle wasting. Following humane destruction, post-mortem...
2.
McCarthy M, Thompson A, Rivers S, Jahanzeb M
Clin Lung Cancer
. 2004 Jan;
1(2):110-7.
PMID: 14733657
It has been known for some time that participation in support groups is beneficial for most cancer survivors. Despite this, and even though lung cancer causes more deaths than breast,...
3.
Richardson J, Prentice D, Rivers S
Adv Skin Wound Care
. 2002 Mar;
14(4):197-203; quiz 204-5.
PMID: 11902345
No abstract available.
4.
Lazar H, Bao Y, Rivers S, Colton T, Bernard S
Ann Thorac Surg
. 2001 Aug;
72(2):548-53; discussion 553-4.
PMID: 11515896
Background: Angiotensin-converting enzyme (ACE) inhibitors differ in their ability to inhibit tissue ACE. This study was, therefore, undertaken to determine whether high tissue affinity ACE inhibitors would improve endothelial function...
5.
Lazar H, Bao Y, Gaudiani J, Rivers S, Marsh H
Circulation
. 1999 Sep;
100(13):1438-42.
PMID: 10500046
Background: Activation of complement during revascularization of ischemic myocardium accentuates myocardial dysfunction. Soluble human complement receptor type 1 (sCR1) is a potent inhibitor of complement, as are heparin-bonded (HB) cardiopulmonary...
6.
Lazar H, Bao Y, Rivers S, Treanor P, Shemin R
Ann Thorac Surg
. 1999 Apr;
67(2):446-9.
PMID: 10197668
Background: This experimental study sought to determine whether heparin-bonding of intraaortic balloons (IAB) would decrease the incidence of arterial thrombosis in the absence of systemic heparinization. Methods: In 25 adult...
7.
Munro A, Noble M, Miles C, Daff S, Green A, Quaroni L, et al.
Biochem Soc Trans
. 1999 Mar;
27(2):190-6.
PMID: 10093732
No abstract available.
8.
Lazar H, Volpe C, Bao Y, Rivers S, Vita J, Keaney Jr J
Ann Thorac Surg
. 1998 Sep;
66(2):487-92.
PMID: 9725390
Background: This experimental study was undertaken to determine whether using angiotensin-converting enzyme inhibitors during surgical revascularization of acutely ischemic myocardium would improve wall motion and limit infarct size. Methods: Twenty...
9.
Lazar H, Hamasaki T, Bao Y, Rivers S, Bernard S, Shemin R
Ann Thorac Surg
. 1998 May;
65(4):973-7.
PMID: 9564912
Background: This study was undertaken to determine whether suppression of complement activation with soluble human complement receptor type I reduces myocardial damage during the revascularization of ischemic myocardium. Methods: In...
10.
Lazar H, Zhang X, Hamasaki T, Memmelo C, Treanor P, Rivers S, et al.
Ann Thorac Surg
. 1997 Jun;
63(6):1701-5.
PMID: 9205170
Background: Heparin-bonded cardiopulmonary bypass circuits reduce complement activation, but their effect on myocardial function is unknown. This study was undertaken to determine whether heparin-bonded circuits reduce myocardial damage during acute...